Research

Learn about published research as well as leading-edge basic and translational research initiatives from St. Jude laboratories.

Heme synthesis linked with acute myeloid leukemia

Blood's oxygen transporter revealed as power source for aggressive pediatric cancer

John Schuetz, PhD

Read how the oncogene MYCN hijacks an oxygen-carrying component of hemoglobin to feed and grow aggressive AML in children.

ASH 2017: Preliminary results show gene therapy gains in X-linked SCID

ASH 2017: Preliminary results show gene therapy gains in SCID

Ewelina Mamcarz, MD

Gene therapy for X-linked SCID resulted in the development of T cell, B cell and natural killer cells without side effects. Read more about the research.

ASH 2017: The role of GATA3 in Ph-like acute lymphoblastic leukemia

ASH 2017: GATA3 in Ph-like acute lymphoblastic leukemia

Jun Yang, PhD

Jun J. Yang, PhD, shares research presented at ASH that highlights the role the GATA3 oncogene plays in a high-risk subset of acute lymphoblastic leukemia.

ASH17: Research on TP53 gene variations presented at first ALL session

ASH 2017: Research on TP53 gene variations featured in first ALL session

Jun Yang, PhD

Jun J. Yang, PhD, offers highlights of the first ALL session at the American Society of Hematology (ASH) meeting, including his work on TP53. Read more.

Math helps biologist calculate variance of blood progenitor cells

Miguel Ganuza, PhD

Find out how a researcher applied statistical analysis to chart variance and better understand how childhood leukemia develops.

Sickle cell study on path to improving therapies for children and adults

Jane Hankins, MD

The Sickle Cell Clinical Research and Intervention Program uses data to determine therapies for children and adults. Learn more.

Brain studies provide treatment clues in unexpected fields

Stanislav Zakharenko, MD, PhD

Research shows possible path to restoring critical regions of the brain involved with hearing loss by limiting a neuromodulator in the auditory thalamus.

Supercharging T cells to fight cancer

Ben Youngblood, PhD

St. Jude researchers are combining therapeutic methods that induce epigenetic reprogramming with immune checkpoint blockade to enhance cancer treatments.